Form: SCHEDULE 13G/A

February 10, 2025






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  This percentage is calculated based upon 3,000,788 common stock as of December 31, 2024, as reported by the Issuer on the 10Q filed. However, as more fully described in Item 4, the securities reported in rows 6, 8, and 9 show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8, and 9. (6)250,555 shares of Common Stock 464,676 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6) 250,555 shares of Common Stock 464,676 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6)250,555 shares of Common Stock 464,676 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Comment for Type of Reporting Person:  (6)250,555 shares of Common Stock 464,676 Shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G


 
Rosalind Advisors, Inc.
 
Signature: Steven Salamon
Name/Title: President
Date: 02/10/2025
 
SALAMON STEVEN A J
 
Signature: Steven Salamon
Name/Title: Steven Salamon
Date: 02/10/2025
 
Aharon Gil
 
Signature: Gil Aharon
Name/Title: Gil Aharon
Date: 02/10/2025
 
Rosalind Master Fund L.P.
 
Signature: Mike McDonald
Name/Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date: 02/10/2025